Cover Image
Market Research Report

Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2025

Published by MarketsandMarkets Product code 933136
Published Content info 268 Pages
Delivery time: 1-2 business days
Price
Back to Top
Contract Research Organization Services (CROs) Market by Type (Discovery, CMC, Preclinical, Clinical Research, Laboratory Services), Therapeutic Area (Oncology, CNS, Cardiovascular), End User (Pharmaceuticals & Medical Device) - Global Forecast to 2025
Published: April 17, 2020 Content info: 268 Pages
Description

"The Contract Research Organization (CRO) services market is projected to grow at a CAGR of 9.1% between 2020 and 2025."

The CRO services market is expected to reach USD 73.77 billion by 2025 from USD 47.77 billion in 2020, at a CAGR of 9.1% from 2020 to 2025. Increased outsourcing of R&D activities and an increasing number of clinical trials are some of the major factors driving the growth of this market. However, lack of skilled labor in the CRO services market is one of the major challenges for the players operating in CROs market.

"Data management services segment to witness the highest growth rate during the forecast period."

Among the CRO services, the laboratory services segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is attributed to the growing outsourcing of data management services by pharmaceutical and biopharmaceutical companies.

"Oncology segment to grow at the highest CAGR from 2020 to 2025."

The oncology segment is expected to grow at the highest CAGR during the forecast period. The increasing number of clinical trials and the rising prevalence of cancer worldwide are the major factors supporting its growth during the forecast period.

"APAC to witness the highest growth rate during the forecast period."

The Asia Pacific region is expected to witness the highest CAGR during the forecast period, owing to the rapid growth in the pharmaceutical and biopharmaceutical industry, low cost of clinical trials, rising number of CROs, and favorable government policies in the region.

Break of Primary Participants:

  • By Company Type - Tier 1: 42%, Tier 2-13%, and Tier 3-45%
  • By Designation - C Level: 17%, Director Level: 25%, and Others: 58%
  • By Region - North America: 20%, Europe: 28%, Asia Pacific: 18%, Latin America: 25%, and the Middle East & Africa: 9%

Research Coverage:

The report analyzes the various CRO services and their adoption patterns in the market. It aims at estimating the market size and future growth potential of the global CRO services market for different segments such as type, therapeutic area, end user, and region. The report also includes an in-depth competitive analysis of the key players in this market along with their company profiles, service offerings, recent developments, and key market strategies.

Reasons to Buy the Report:

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them garner a greater share. Firms purchasing the report could use any one or combination of the below-mentioned strategies for strengthening their market positions.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the service portfolios offered by the top players in the CRO services market
  • Service Launch/Innovation: Detailed insights on new service launches in the CRO services market
  • Market Development: Comprehensive information about lucrative emerging markets, by type, therapeutic area, end user, and region
  • Market Diversification: Exhaustive information about new services, growing geographies, recent developments in the CRO services market
  • Competitive Assessment: In-depth assessment of growth strategies, services, and manufacturing capabilities of leading players in the CRO services market
Table of Contents
Product Code: PH 4672

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 MARKETS COVERED
    • 1.2.2 YEARS CONSIDERED FOR THE STUDY
  • 1.3 CURRENCY
  • 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY SOURCES
      • 2.1.1.1 Key data from secondary sources
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Key data from primary sources
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 REVENUE SHARE ANALYSIS
    • 2.2.2 ILLUSTRATION OF COMPANY REVENUE ANALYSIS
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
  • 2.4 MARKET SHARE ESTIMATION
  • 2.5 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 CRO SERVICES MARKET OVERVIEW
  • 4.2 ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE AND COUNTRY
  • 4.3 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.4 CRO SERVICES MARKET: GEOGRAPHIC MIX
  • 4.5 CRO SERVICES MARKET: DEVELOPING VS. DEVELOPED COUNTRIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growth in R&D spending
      • 5.2.1.2 Increasing number of clinical trials
      • 5.2.1.3 High cost of in-house drug development
      • 5.2.1.4 Rising prevalence of orphan and rare diseases
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Growth in the biosimilars and biologics markets
      • 5.2.2.2 Rising demand for specialized testing services
      • 5.2.2.3 Increasing outsourcing activities to emerging Asian economies
    • 5.2.3 CHALLENGES
      • 5.2.3.1 Shortage of skilled professionals
    • 5.2.4 TRENDS
      • 5.2.4.1 Revolutionary shift in the CRO services market due to the growing adoption of artificial intelligence-based tools for drug discovery

6 CRO SERVICES MARKET, BY TYPE

  • 6.1 INTRODUCTION
  • 6.2 CLINICAL RESEARCH SERVICES
    • 6.2.1 PHASE III CLINICAL RESEARCH SERVICES
      • 6.2.1.1 Phase III clinical services are the most expensive with several thousand patients being recruited for each study
    • 6.2.2 PHASE II CLINICAL RESEARCH SERVICES
      • 6.2.2.1 Phase II clinical studies can last up to two years and provide an indication on the clinical efficacy of a drug or a device
    • 6.2.3 PHASE IV CLINICAL RESEARCH SERVICES
      • 6.2.3.1 Phase IV clinical studies are usually conducted post-marketing of drugs to evaluate adverse drug reactions
    • 6.2.4 PHASE I CLINICAL RESEARCH SERVICES
      • 6.2.4.1 Phase I clinical studies usually provide an indication on maximum tolerated dose of a new treatment
  • 6.3 EARLY-PHASE DEVELOPMENT SERVICES
    • 6.3.1 CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES
      • 6.3.1.1 CMC services include a host of testing such as API/product release, stability, and dissolution
    • 6.3.2 PRECLINICAL SERVICES
      • 6.3.2.1 Pharmacokinetics/pharmacodynamics
        • 6.3.2.1.1 PK/PD services segment accounted for the largest share of the preclinical services market
      • 6.3.2.2 Toxicology testing services
        • 6.3.2.2.1 Toxicology testing is crucial in checking and confirming the quality, efficacy, and safety of new drug substances
      • 6.3.2.3 Other preclinical services
    • 6.3.3 DISCOVERY STUDIES
      • 6.3.3.1 Growing number of rare diseases to promote the growth of this segment
  • 6.4 LABORATORY SERVICES
    • 6.4.1 BIOANALYTICAL TESTING SERVICES
      • 6.4.1.1 Bioanalytical testing services are required to establish the safety and efficacy of complex large molecules
    • 6.4.2 ANALYTICAL TESTING SERVICES
      • 6.4.2.1 Physical characterization services
        • 6.4.2.1.1 Increasing use of nanoparticles is driving the need for physical characterization studies
      • 6.4.2.2 Raw material testing services
        • 6.4.2.2.1 These services are performed from the early stages of product development to the commercial batch-release stages
      • 6.4.2.3 Batch-release testing services
        • 6.4.2.3.1 Batch-release testing services include disintegration, dissolution, hardness, and elemental impurities testing
      • 6.4.2.4 Stability testing services
        • 6.4.2.4.1 Stability testing studies ensure the quality, safety, and efficacy of a pharmaceutical product throughout its shelf life
      • 6.4.2.5 Other analytical testing services
  • 6.5 CONSULTING SERVICES
    • 6.5.1 CONSULTING SERVICES ARE UTILIZED FOR DRUG DEVELOPMENT AND REGULATORY STRATEGIES
  • 6.6 DATA MANAGEMENT SERVICES
    • 6.6.1 DATA MANAGEMENT SERVICES ARE EXPECTED TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD

7 CRO SERVICES MARKET, BY THERAPEUTIC AREA

  • 7.1 INTRODUCTION
  • 7.2 ONCOLOGY
    • 7.2.1 INCREASING NUMBER OF CANCER CASES DRIVING THE GROWTH OF THIS SEGMENT
  • 7.3 CENTRAL NERVOUS SYSTEM DISORDERS
    • 7.3.1 INCREASING AWARENESS RELATED TO NEUROLOGICAL DISORDERS DRIVING RESEARCH IN THIS AREA
  • 7.4 INFECTIOUS DISEASES
    • 7.4.1 INCREASING EPIDEMIC OUTBREAKS CALLING FOR INCREASING DRUG DISCOVERY ACTIVITIES RELATED TO INFECTIOUS DISEASES
  • 7.5 CARDIOVASCULAR SYSTEM DISORDERS
    • 7.5.1 HIGH CVS DISORDER-RELATED MORTALITY IS DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
  • 7.6 METABOLIC DISORDERS
    • 7.6.1 GROWING GLOBAL DIABETES POPULATION IS EXPECTED TO DRIVE MARKET GROWTH
  • 7.7 IMMUNOLOGICAL DISORDERS
    • 7.7.1 GROWING IMMUNOLOGICAL DRUGS PIPELINE IS RESULTING IN AN INCREASE IN OUTSOURCING ACTIVITIES
  • 7.8 RESPIRATORY DISORDERS
    • 7.8.1 COPD IS ONE OF THE MAJOR CAUSES OF DEATHS GLOBALLY
  • 7.9 OPHTHALMOLOGY DISORDERS
    • 7.9.1 RETINA, GLAUCOMA, AND MACULAR DEGENERATION TRIALS DOMINATE OPHTHALMOLOGY RELATED CLINICAL TRIALS
  • 7.10 OTHER THERAPEUTIC AREAS

8 CRO SERVICES MARKET, BY END USER

  • 8.1 INTRODUCTION
  • 8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 8.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINE TO DRIVE MARKET GROWTH
  • 8.3 MEDICAL DEVICE COMPANIES
    • 8.3.1 INCREASE IN R&D FOR DEVELOPMENT OF ADVANCED MEDICAL DEVICES IS FUELING MARKET GROWTH
  • 8.4 ACADEMIC INSTITUTES
    • 8.4.1 ACADEMIA-INDUSTRY COLLABORATIONS PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT

9 CRO SERVICES MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 US
      • 9.2.1.1 US is the largest market for CRO services in North America
    • 9.2.2 CANADA
      • 9.2.2.1 Increasing number of clinical trials in Canada to support market growth
  • 9.3 EUROPE
    • 9.3.1 GERMANY
      • 9.3.1.1 Government support and flexible labor laws have made Germany a favorable location for clinical trials
    • 9.3.2 UK
      • 9.3.2.1 Investment by pharmaceutical sponsors in the UK for drug discovery services to support market growth
    • 9.3.3 FRANCE
      • 9.3.3.1 High number of oncology clinical trials in France to drive market growth
    • 9.3.4 ITALY
      • 9.3.4.1 Low drug approval time in Italy, along with the growing number of clinical trials, to drive market growth
    • 9.3.5 SPAIN
      • 9.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 CHINA
      • 9.4.1.1 China dominated the CRO services market in the Asia Pacific
    • 9.4.2 JAPAN
      • 9.4.2.1 Rising geriatric population to drive market growth in Japan
    • 9.4.3 INDIA
      • 9.4.3.1 Growing pharmaceutical industry in India to drive market growth
    • 9.4.4 AUSTRALIA
      • 9.4.4.1 Australia is a favorable location for drug discovery due to a large number of research institutes in the country
    • 9.4.5 SOUTH KOREA
      • 9.4.5.1 Growing R&D expenditure in South Korea to drive market growth
    • 9.4.6 REST OF ASIA PACIFIC
  • 9.5 LATIN AMERICA
    • 9.5.1 GROWING R&D EXPENDITURE IN THE PHARMACEUTICAL AND BIOPHARMACEUTICAL SECTOR TO DRIVE MARKET GROWTH IN LATIN AMERICA
  • 9.6 MIDDLE EAST & AFRICA
    • 9.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH IN THE MIDDLE EAST AND AFRICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 MARKET SHARE ANALYSIS: CRO SERVICES MARKET (2019)
  • 10.3 COMPETITIVE LEADERSHIP MAPPING
    • 10.3.1 VISIONARY LEADERS
    • 10.3.2 INNOVATORS
    • 10.3.3 DYNAMIC DIFFERENTIATORS
    • 10.3.4 EMERGING COMPANIES
  • 10.4 COMPETITIVE SITUATION AND TRENDS
    • 10.4.1 SERVICE LAUNCHES
    • 10.4.2 EXPANSIONS
    • 10.4.3 ACQUISITIONS
    • 10.4.4 PARTNERSHIPS & AGREEMENTS

11 COMPANY PROFILES

(Business Overview, Products Offered, Recent Developments, MnM View, Strategic Overview)*

  • 11.1 IQVIA
  • 11.2 LABCORP
  • 11.3 SYNEOS HEALTH INC.
  • 11.4 WUXI APPTEC
  • 11.5 CHARLES RIVER LABORATORIES
  • 11.6 PAREXEL INTERNATIONAL
  • 11.7 PRA HEALTH SCIENCES
  • 11.8 PPD
  • 11.9 ICON PLC
  • 11.10 MEDPACE HOLDINGS
  • 11.11 SGS
  • 11.12 PSI CRO AG
  • 11.13 AXCENT ADVANCED ANALYTICS
  • 11.14 BIOAGILE THERAPEUTICS
  • 11.15 FIRMA CLINICAL RESEARCH
  • 11.16 ACCULAB LIFESCIENCES
  • 11.17 AZELIX
  • 11.18 CTSERV
  • 11.19 PEPGRA
  • 11.20 DOVE QUALITY SOLUTIONS

Business Overview, Products Offered, Recent Developments, MnM View Strategic Overview, might not be captured in case of unlisted companies.

12 APPENDIX

  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1 RESEARCH PROJECTS FUNDED BY THE INTERNATIONAL RARE DISEASES RESEARCH CONSORTIUM, 2019
  • TABLE 2 LIST OF BIOLOGICAL LICENSE APPLICATION APPROVALS IN THE US, 2019
  • TABLE 3 CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 4 CRO SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 5 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF MARCH 2020, BY LOCATION
  • TABLE 6 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
  • TABLE 7 CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 8 CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 9 EXAMPLES OF DRUGS THAT COMPLETED PHASE III STUDIES
  • TABLE 10 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 11 EXAMPLES OF DRUGS THAT COMPLETED PHASE II STUDIES
  • TABLE 12 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 13 EXAMPLES OF DRUGS THAT COMPLETED PHASE IV CLINICAL STUDIES
  • TABLE 14 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 15 EXAMPLES OF DRUGS AND MEDICAL DEVICES THAT COMPLETED PHASE I STUDIES
  • TABLE 16 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 17 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS
  • TABLE 18 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 19 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 20 CHEMISTRY, MANUFACTURING, AND CONTROL SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 21 PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 22 PRECLINICAL SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 23 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 24 TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 25 OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 26 DISCOVERY STUDIES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 27 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
  • TABLE 28 LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 29 LABORATORY SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 30 BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 31 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 32 ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 33 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 34 RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 35 BATCH-RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 36 STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 37 OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 38 EXAMPLES OF CONSULTING SERVICES OFFERED BY PROMINENT PLAYERS
  • TABLE 39 CONSULTING SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 40 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
  • TABLE 41 DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 42 GLOBAL NUMBER OF CLINICAL TRIALS IN DIFFERENT THERAPEUTIC AREAS, 2015-2018
  • TABLE 43 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 44 LIST OF PIPELINE DRUGS FOR ONCOLOGY (2018)
  • TABLE 45 CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 46 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2018)
  • TABLE 47 CRO SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 48 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 49 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2018)
  • TABLE 50 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 51 CRO SERVICES MARKET FOR METABOLIC DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 52 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 53 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2018)
  • TABLE 54 CRO SERVICES MARKET FOR RESPIRATORY DISEASES, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 55 CRO SERVICES MARKET FOR OPHTHALMOLOGY DISORDERS, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 56 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 57 CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 58 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 59 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 60 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 61 CRO SERVICES MARKET, BY REGION, 2018-2025 (USD MILLION)
  • TABLE 62 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 63 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 64 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 65 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 66 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 67 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 68 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 69 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 70 NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 71 US: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 72 US: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 73 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 74 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 75 US: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 76 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 77 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 78 US: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 79 NUMBER OF ACTIVE CLINICAL TRIALS IN CANADA, BY CONDITION (2019)
  • TABLE 80 CANADA: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 81 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 82 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 83 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 84 CANADA: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 85 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 86 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 87 CANADA: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 88 EUROPE: NUMBER OF COMMERCIAL CLINICAL TRIALS STARTED IN 2017, BY PHASE
  • TABLE 89 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 90 EUROPE: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 91 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 92 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 93 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 94 EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 95 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 96 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 97 EUROPE: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 98 GERMANY: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 99 GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 100 GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 101 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 102 GERMANY: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 103 GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 104 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 105 GERMANY: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 106 UK: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 107 UK: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 108 UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 109 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 110 UK: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 111 UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 112 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 113 UK: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 114 FRANCE: NUMBER OF COMMERCIAL CLINICAL TRIALS STARTED IN 2017, BY COMPANY
  • TABLE 115 FRANCE: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 116 FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 117 FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 118 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 119 FRANCE: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 120 FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 121 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 122 FRANCE: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 123 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (2017)
  • TABLE 124 ITALY: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 125 ITALY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 126 ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 127 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 128 ITALY: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 129 ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 130 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 131 ITALY: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 132 SPAIN: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 133 SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 134 SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 135 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 136 SPAIN: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 137 SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 138 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 139 SPAIN: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 140 ROE: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 141 CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 142 ROE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 143 ROE: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 144 ROE: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 145 ROE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 146 ROE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 147 ROE: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 148 TOTAL NUMBER OF CLINICAL TRIALS IN THE ASIA PACIFIC, BY THERAPEUTIC AREA, 2017 VS. 2019
  • TABLE 149 ASIA PACIFIC: CRO SERVICES MARKET, BY COUNTRY, 2018-2025 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 152 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 153 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 154 ASIA PACIFIC: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 156 ASIA PACIFIC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 158 TOTAL NUMBER OF CLINICAL TRIALS IN CHINA, BY THERAPEUTIC AREA, 2017 VS. 2019
  • TABLE 159 CHINA: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 160 CHINA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 161 CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 162 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 163 CHINA: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 164 CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 165 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 166 CHINA: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 167 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2017 VS. 2019
  • TABLE 168 JAPAN: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 169 JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 170 JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 171 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 172 JAPAN: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 173 JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 174 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 175 JAPAN: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 176 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2017 VS. 2019
  • TABLE 177 INCREASE IN R&D EXPENDITURE OF TOP 5 INDIAN PHARMACEUTICAL COMPANIES (2010 VS. 2018)
  • TABLE 178 INDIA: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 179 INDIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 180 INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 181 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 182 INDIA: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 183 INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 184 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 185 INDIA: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 186 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 187 AUSTRALIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 188 AUSTRALIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 189 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 190 AUSTRALIA: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 191 AUSTRALIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 192 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 193 AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 194 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 195 SOUTH KOREA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 196 SOUTH KOREA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 197 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 198 SOUTH KOREA: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 199 SOUTH KOREA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 200 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 201 SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 202 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA, BY THERAPEUTIC AREA, 2017 VS. 2019
  • TABLE 203 ROAPAC: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 204 ROAPAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 205 ROAPAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 206 ROAPAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 207 ROAPAC: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 208 ROAPAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 209 ROAPAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 210 ROAPAC: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 211 CLINICAL TRIALS FOR DIFFERENT THERAPEUTIC AREAS IN LATINA AMERICA (2017)
  • TABLE 212 NUMBER OF CLINICAL TRIALS IN LATINA AMERICA, BY COUNTRY
  • TABLE 213 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 214 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 215 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 216 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 217 LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 218 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 219 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 220 LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 221 CLINICAL TRIALS FOR DIFFERENT THERAPEUTIC AREAS IN MIDDLE EAST AND AFRICA (2017)
  • TABLE 222 NUMBER OF CLINICAL TRIALS IN THE MIDDLE EAST AND AFRICA, BY COUNTRY (2019)
  • TABLE 223 MIDDLE EAST AND AFRICA: CRO SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 224 MIDDLE EAST AND AFRICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2018-2025 (USD MILLION)
  • TABLE 225 MIDDLE EAST AND AFRICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 226 MIDDLE EAST AND AFRICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 227 MIDDLE EAST AND AFRICA: LABORATORY SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 228 MIDDLE EAST AND AFRICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2018-2025 (USD MILLION)
  • TABLE 229 MIDDLE EAST AND AFRICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2018-2025 (USD MILLION)
  • TABLE 230 MIDDLE EAST AND AFRICA: CRO SERVICES MARKET, BY END USER, 2018-2025 (USD MILLION)
  • TABLE 231 SERVICE LAUNCHES, 2017-2020
  • TABLE 232 EXPANSIONS, 2017-2020
  • TABLE 233 ACQUISITIONS, 2017-2020
  • TABLE 234 PARTNERSHIPS & AGREEMENTS, 2017-2020

LIST OF FIGURES

  • FIGURE 1 CONTRACT RESEARCH ORGANIZATION SERVICES MARKET
  • FIGURE 2 RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 DATA TRIANGULATION METHODOLOGY
  • FIGURE 5 CRO SERVICES MARKET, BY TYPE, 2020 VS. 2025 (USD MILLION)
  • FIGURE 6 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2020 VS. 2025 (USD MILLION)
  • FIGURE 7 CRO SERVICES MARKET, BY END USER, 2020 VS. 2025 (USD MILLION)
  • FIGURE 8 GEOGRAPHIC SNAPSHOT: CRO SERVICES MARKET
  • FIGURE 9 GROWING R&D EXPENDITURE AND INCREASE IN THE NUMBER OF CLINICAL TRIALS TO DRIVE MARKET GROWTH DURING THE FORECAST PERIOD
  • FIGURE 10 CHINA DOMINATED THE APAC CRO SERVICES MARKET IN 2019
  • FIGURE 11 CHINA TO GROW AT THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 12 NORTH AMERICA TO CONTINUE TO DOMINATE THE CRO SERVICES MARKET DURING THE FORECAST PERIOD
  • FIGURE 13 DEVELOPING COUNTRIES TO PRESENT HIGH GROWTH OPPORTUNITIES TO MARKET PLAYERS DURING THE FORECAST PERIOD
  • FIGURE 14 CRO SERVICES MARKET: DRIVERS, OPPORTUNITIES, CHALLENGES, AND TRENDS
  • FIGURE 15 INCREASING R&D SPENDING OF PHRMA MEMBER COMPANIES, 2010-2018
  • FIGURE 16 ACTIVE PHARMACEUTICAL PIPELINE, 2009-2019
  • FIGURE 17 INCREASING NUMBER OF CLINICAL TRIALS WORLDWIDE (2002-2020)
  • FIGURE 18 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2013-2019 (USD BILLION)
  • FIGURE 19 TOTAL NUMBER OF NEW BIOLOGIC LICENSE APPLICATION FILINGS, APPROVALS, AND NDA APPROVALS (2005-2019)
  • FIGURE 20 NUMBER OF CLINICAL TRIALS, 2010-2020
  • FIGURE 21 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2018 VS. 2019
  • FIGURE 22 BIOPHARMACEUTICAL DRUGS IN DEVELOPMENT IN THE US, BY THERAPEUTIC AREA (2019)
  • FIGURE 23 PHASES OF DRUG DISCOVERY STUDIES
  • FIGURE 24 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2018)
  • FIGURE 25 TOTAL NUMBER OF CLINICAL TRIALS FOR ONCOLOGY (2017)
  • FIGURE 26 PREVALENCE OF DIAGNOSED INFECTIOUS DISEASES IN SELECTED COUNTRIES (2019)
  • FIGURE 27 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLION)
  • FIGURE 28 ANNUAL DRUG APPROVALS BY CDER (2009-2018)
  • FIGURE 29 R&D SPENDING OF PHARMA MEMBER COMPANIES, 2011-2018
  • FIGURE 30 ACTIVE PHARMACEUTICAL PIPELINE, 2009-2019
  • FIGURE 31 APPROVED NUMBER OF CLINICAL TRIALS WORLDWIDE (2000-2018)
  • FIGURE 32 R&D SPENDING OF LEADING MEDICAL DEVICE COMPANIES (IN USD MILLION), 2018
  • FIGURE 33 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • FIGURE 34 TOTAL NUMBER OF CLINICAL TRIALS: GLOBAL VS. NORTH AMERICA (2019)
  • FIGURE 35 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT
  • FIGURE 36 US: PIPELINE SPLIT OF PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY PHASE (JANUARY 2019)
  • FIGURE 37 TOTAL R&D EXPENDITURE OF THE US PHARMACEUTICAL INDUSTRY (2010-2018)
  • FIGURE 38 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013-2017 (USD MILLION)
  • FIGURE 39 SPAIN: PHARMACEUTICAL R&D EXPENDITURE, 2011-2017
  • FIGURE 40 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT
  • FIGURE 41 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS-KEY GROWTH STRATEGY ADOPTED BY SOME MARKET PLAYERS FROM JANUARY 2017 TO JANUARY 2020
  • FIGURE 42 CRO SERVICES MARKET SHARE, BY KEY PLAYER, 2019
  • FIGURE 43 CRO SERVICES MARKET: COMPETITIVE LEADERSHIP MAPPING (2019)
  • FIGURE 44 IQVIA: COMPANY SNAPSHOT (2019)
  • FIGURE 45 LABCORP: COMPANY SNAPSHOT (2019)
  • FIGURE 46 SYNEOS HEALTH INC.: COMPANY SNAPSHOT (2019)
  • FIGURE 47 WUXI APPTEC: COMPANY SNAPSHOT (2018)
  • FIGURE 48 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2019)
  • FIGURE 49 PRA HEALTH SCIENCES: COMPANY SNAPSHOT (2018)
  • FIGURE 50 ICON: COMPANY SNAPSHOT (2019)
  • FIGURE 51 MEDPACE HOLDINGS: COMPANY SNAPSHOT (2018)
  • FIGURE 52 SGS: COMPANY SNAPSHOT (2019)
Back to Top